|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Abbott |
| Information provided by: | Abbott |
| ClinicalTrials.gov Identifier: | NCT00073151 |
Purpose
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
| Condition | Intervention | Phase |
|
Non-Small Cell Lung Cancer |
Drug: ABT-751 |
Phase II |
| MedlinePlus related topics: | Cancer Lung Cancer |
| Drug Information available for: | ABT 751 E 7010 |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens |
| Estimated Enrollment: | 30 |
| Study Start Date: | September 2003 |
| Study Completion Date: | January 2006 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, Florida | |||||
| Oncology Hematology Group of South Florida | |||||
| Miami, Florida, United States | |||||
| Florida Cancer Institute | |||||
| New Port Richey, Florida, United States | |||||
| United States, Illinois | |||||
| University of Chicago Medical Center | |||||
| Chicago, Illinois, United States, 60637-1460 | |||||
| United States, Maryland | |||||
| University of Maryland Greenbaum Cancer Center | |||||
| Baltimore, Maryland, United States, 21201-1595 | |||||
| United States, Missouri | |||||
| Washington University School of Medicine | |||||
| St. Louis, Missouri, United States, 63110-1093 | |||||
| Oncology & Hematology Associates of Kansas City, PA | |||||
| Kansas City, Missouri, United States, 64111 | |||||
| United States, New York | |||||
| Albany Regional Cancer Center | |||||
| Albany, New York, United States | |||||
| United States, North Carolina | |||||
| Raleigh Hematology Oncology | |||||
| Cary, North Carolina, United States | |||||
| United States, Ohio | |||||
| Dayton Oncology and Hematology | |||||
| Kettering, Ohio, United States | |||||
| United States, Oklahoma | |||||
| Cancer Care Associates | |||||
| Oklahoma City, Oklahoma, United States | |||||
| United States, South Carolina | |||||
| Cancer Centers of the Carolinas | |||||
| Greenville, South Carolina, United States | |||||
| United States, Tennessee | |||||
| West Cancer Clinic | |||||
| Memphis, Tennessee, United States, 38120 | |||||
| United States, Texas | |||||
| Texas Oncology | |||||
| Dallas, Texas, United States | |||||
| Texas Oncology | |||||
| Dallas, Texas, United States | |||||
| Texas Oncology | |||||
| Ft. Worth, Texas, United States | |||||
| United States, Washington | |||||
| Cancer Care Northwest | |||||
| Spokane, Washington, United States | |||||
| Northwest Cancer Specialists | |||||
| Vancouver, Washington, United States | |||||
| United States, Wisconsin | |||||
| University of Wisconsin Comprehensive Cancer Center | |||||
| Madison, Wisconsin, United States, 53792-5666 | |||||
| Abbott |
| Study Director: | Helen Eliopoulos, MD | Abbott |
More Information
| Study ID Numbers: | M02-448 |
| First Received: | November 17, 2003 |
| Last Updated: | November 28, 2007 |
| ClinicalTrials.gov Identifier: | NCT00073151 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|